STTK - NASDAQ

Shattuck Labs, Inc.

Shattuck Labs, Inc.

STTK·NASDAQ

$4.89

+0.43%
HealthcareBiotechnology

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$234.29M
EPS-0.7000
P/E Ratio-6.99
Earnings Date08/06/2026

Available Earnings Call Transcripts

Select a year and quarter to view the full transcript.

Shattuck Labs, Inc.

Shattuck Labs, Inc. Earnings Call Transcripts

STTK · NASDAQ

2023

1
Q3
Nov 10
Q1
N/A
Q2
N/A
Q4
N/A

2022

2
Q3
Nov 12
Q4
Feb 26
Q1
N/A
Q2
N/A

2021

1
Q2
Aug 14
Q1
N/A
Q3
N/A
Q4
N/A

Related Guides

Blog Categories

Continue your STTK research with focused valuation guides.

Forecasting

Compare management guidance with modeled outcomes.

Risk Analysis

Track estimate risk, misses, and downside scenarios.

Reference

Review analyst process and transcript interpretation.

Value Investing

Anchor quarterly narrative to intrinsic value discipline.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.